The risk of @entity910 ( @entity910 ) increases with advancing age. @entity1767 increases striatal oxidative stress and inhibits @entity842 (NO) synthase (NOS) in vitro. Biological aging is associated with increased oxidative stress and reduced brain NOS activity. This paper has explored aging and striatal NOS activity ex vivo as co-morbid factors in an animal model of @entity910 . Young adult, mature adult and aged @entity35 were treated with water or @entity1767 (1.5 mg/kg per day) for 12 weeks. Vacous chewing movements (VCM) were monitored, as was striatal NOS activity. Aging significantly increased spontaneous VCM in mature and aged animals and progressively attenuated NOS activity in both mature adult and aged @entity35 compared to young animals, and numerically lower in aged versus mature adult animals. @entity1767 significantly increased VCM in all age groups, while significantly reducing NOS activity in young and mature adults but not aged. Reduced NOS activity after @entity1767 treatment was significantly lower in mature compared to young @entity35 , but only numerically lower in aged @entity35 receiving the drug, with a slight increase noted in the latter. In the current model, aging did not markedly alter @entity1767 -induced VCM. Abrogated striatal nitrergic activity, therefore, underlies aging and @entity1767 -induced VCM. Compensatory nitrergic mechanisms may preclude @entity1155 and @entity910 under conditions of advanced age and NOS inhibition.

Role of aging and striatal XXXX synthase activity in an animal model of @entity910 .

@entity910 :: ('MESH:D004409', 'Disease') :: ['dyskinesia', 'TD', 'tardive dyskinesia'] @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide'] @entity1767 :: ('MESH:D006220', 'Chemical') :: ['haloperidol', 'Haloperidol'] @entity1155 :: ('MESH:D011596', 'Disease') :: ['progressive NOS suppression'] @entity35 :: ('10116', 'Species') :: ['rats']
@entity842 :: (MESH:D009569,Chemical) :: ['nitric oxide']
